阿柏西普治疗息肉样脉络膜血管病变的效果  

The efficacy of aflibercept in the treatment of polypoidal choroidal vasculopathy

作　　者：郭静君[1] 申战省[1] 陈梦平[1] 赵宏[1] Guo Jingjun;Shen Zhansheng;Chen Mengping;Zhao Hong(Department of Ophthalmology,Zhengzhou Second People’s Hospital,Zhengzhou Ophthalmology Hospital,Zhengzhou 450006,China)

机构地区：[1]郑州市第二人民医院眼科郑州市眼科医院,450006

出　　处：《中华眼外伤职业眼病杂志》2021年第11期819-825,共7页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的观察玻璃体内注射阿柏西普治疗息肉样脉络膜血管病变(PCV)的临床效果。方法回顾性分析郑州市第二人民医院2018年6月至2019年6月28例(31只眼)PCV玻璃体内注射阿柏西普的临床资料,观察治疗后的视力、黄斑中心区厚度(CMT)及息肉消除率等。随访12个月。结果治疗后3、6及12个月的视力优于治疗前(P<0.05);CMT较治疗前降低(P<0.05)。治疗后12个月息肉消退者18只眼,消退率为58.06%。息肉消退组玻璃体内注药次数及最长间隔注射时间与息肉未消退组对比差异具有统计学意义(P<0.05)。除一过性高眼压及结膜下出血外,未见严重的全身或局部并发症。结论玻璃体内注射阿柏西普治疗PCV安全有效。Objective To observe the clinical efficacy of intravitreal injection of aflibercept in the treatment for patients with polypoidal choroidal vasculopathy(PCV).Methods This was a retrospective study.The clinical data of 31 eyes of 28 cases of PCV treated with intravitreal injection of aflibercept from Jun.2018 to Jun.2019 in Zhengzhou Second People’s Hospital were analyzed.The best corrected visual acuity,central macular thickness(CMT),the rate of polyp regression and so on were observed.The follow-up time was 12 months.Results At 3,6 and 12 months after treatment,the visual acuity was better than that before treatment(P<0.05),and CMT decreased(P<0.05).There were 18 eyes with polyp regression at 12 months after treatment at the rate of 58.06%.The differences of intravitreal injection frequency and maximum interval injection time between PCV with and without polyp regression were statistically significant(P<0.05).There was no severe systemic or local complication except transient ocular hypertension and subconjunctival hemorrhage.Conclusion Intravitreal injection of aflibercept is a safe and effective therapeutic strategy for PCV.

关 键 词：脉络膜疾病 脉络膜 息肉 血管内皮生长因子A 血管生成抑制剂 

分 类 号：R773.4[医药卫生—眼科]